当前位置:首页 > 报告详情

Almirall JP Morgan 2025.pdf

上传人: c** 编号:603950 2025-02-03 24页 1.69MB

1、J.P.Morgan Healthcare Conference 2025European Medical Dermatology Leader43rd Annual J.P.Morgan Healthcare ConferenceJanuary 20251J.P.Morgan Healthcare Conference 2025This document has been prepared by Almirall,S.A.(the“Company”)exclusively for use duringthe presentation.This document includes onlysu

2、mmary information and does not intend to becomprehensive.Thisdocumentmay notbedisclosed or published or used by any person orentity for any reason without the prior,expresswritten consent of the Company.Information in this document about the price atwhich securities issued by the Company havebeenpur

3、chasedorsoldinthepast,orinformation about the yield on securities issuedby the Company,cannot be relied upon as aguidetothefutureperformanceoftheCompanys securities.Forwardlookinginformation,opinionsandstatements contained herein are based on theCompanys estimates(using assumptions thatthe Company b

4、elieves to be reasonable)and onsources believed to be reliable by the Company,buthavenotbeenverifiedby independentexperts.The Company does not warrant thecompleteness,timeliness or accuracy of anysuch information,opinions and statements,and,accordingly,no reliance should be placed onthem in this con

5、nection.Certain statements contained herein that are nothistorical facts are forward-looking statements.Such forward-looking statements are based oncurrentexpectationsandprojectionsaboutfuture events and are subject to various risksand uncertainties,many of which are difficult topredict and are beyo

6、nd the control of theCompany.Therefore,actual results may differmaterially from those discussed in,or impliedby,such forward-looking statements.Except tothe extent required by the applicable law,theCompany expressly disclaims any obligation toreviseorupdateanyforward-lookingstatements,the expectatio

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
Almirall公司是一家专注于医疗皮肤病学的全球生物制药公司,在欧洲拥有领导地位。该公司致力于通过创新疗法推进皮肤科学,改善患者生活。文章提到了几个关键数据:到2031年,预计用先进疗法治疗的atopic dermatitis患者数量将增长4-5倍;Ilumetri®和Ebglyss®是成为key first-line products for moderate to severe patients;到2028年,Ilumetri®的销售额预计将实现高双位数增长。Almirall公司的研发路线图计划在未来的三年内交付未来的价值,通过创新性的 disruptive innovation 来涵盖广泛的皮肤疾病。此外,Almirall公司还强调了其强大的商业执行能力,以及在皮肤病学领域的长期愿景和增长潜力。
"Almirall公司如何看待未来3年的研发路线图?" "Ebglyss®和Ilumetri®在欧洲医疗皮肤病领域的销售前景如何?" "Almirall公司在新药研发方面有哪些创新和突破?"
客服
商务合作
小程序
服务号
折叠